481 related articles for article (PubMed ID: 25200104)
61. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver.
Zollner G; Wagner M; Fickert P; Geier A; Fuchsbichler A; Silbert D; Gumhold J; Zatloukal K; Kaser A; Tilg H; Denk H; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G798-805. PubMed ID: 16002565
[TBL] [Abstract][Full Text] [Related]
62. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
63. [Effects of farnesoid X receptor ligand on the metabolism of bile acids in rats with estrogen-induced intrahepatic cholestasis of pregnancy].
Zou SL; Liu J; Lan Y; Cheng H; Gan XL
Zhonghua Gan Zang Bing Za Zhi; 2008 May; 16(5):383-6. PubMed ID: 18510855
[TBL] [Abstract][Full Text] [Related]
64. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR.
Carter BA; Taylor OA; Prendergast DR; Zimmerman TL; Von Furstenberg R; Moore DD; Karpen SJ
Pediatr Res; 2007 Sep; 62(3):301-6. PubMed ID: 17622954
[TBL] [Abstract][Full Text] [Related]
65. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
[TBL] [Abstract][Full Text] [Related]
66. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
Modica S; Moschetta A
FEBS Lett; 2006 Oct; 580(23):5492-9. PubMed ID: 16904670
[TBL] [Abstract][Full Text] [Related]
67. Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis.
Hao H; Cao L; Jiang C; Che Y; Zhang S; Takahashi S; Wang G; Gonzalez FJ
Cell Metab; 2017 Apr; 25(4):856-867.e5. PubMed ID: 28380377
[TBL] [Abstract][Full Text] [Related]
68. Bile acid receptors in non-alcoholic fatty liver disease.
Li Y; Jadhav K; Zhang Y
Biochem Pharmacol; 2013 Dec; 86(11):1517-24. PubMed ID: 23988487
[TBL] [Abstract][Full Text] [Related]
69. 1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo.
Chow EC; Durk MR; Cummins CL; Pang KS
J Pharmacol Exp Ther; 2011 Jun; 337(3):846-59. PubMed ID: 21421739
[TBL] [Abstract][Full Text] [Related]
70. A role of the bile salt receptor FXR in atherosclerosis.
Hageman J; Herrema H; Groen AK; Kuipers F
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1519-28. PubMed ID: 20631352
[TBL] [Abstract][Full Text] [Related]
71. A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor.
Narayanan AK; Surendran S; Balakrishnan D; Gopalakrishnan U; Malick S; Valsan A; Philips CA; Watson CJE
Curr Rev Clin Exp Pharmacol; 2024; 19(3):225-233. PubMed ID: 38708917
[TBL] [Abstract][Full Text] [Related]
72. Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders.
Fiorucci S; Zampella A; Distrutti E
Curr Top Med Chem; 2012; 12(6):605-24. PubMed ID: 22242859
[TBL] [Abstract][Full Text] [Related]
73. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
[TBL] [Abstract][Full Text] [Related]
74. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
Claudel T; Staels B; Kuipers F
Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
[TBL] [Abstract][Full Text] [Related]
75. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype.
Abu-Hayyeh S; Papacleovoulou G; Lövgren-Sandblom A; Tahir M; Oduwole O; Jamaludin NA; Ravat S; Nikolova V; Chambers J; Selden C; Rees M; Marschall HU; Parker MG; Williamson C
Hepatology; 2013 Feb; 57(2):716-26. PubMed ID: 22961653
[TBL] [Abstract][Full Text] [Related]
76. Bile Acids as Hormones: The FXR-FGF15/19 Pathway.
Kliewer SA; Mangelsdorf DJ
Dig Dis; 2015; 33(3):327-31. PubMed ID: 26045265
[TBL] [Abstract][Full Text] [Related]
77. Makisterone A attenuates experimental cholestasis by activating the farnesoid X receptor.
Kang P; Li S
Biochem Biophys Res Commun; 2022 Oct; 623():162-169. PubMed ID: 35921707
[TBL] [Abstract][Full Text] [Related]
78. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors.
Makishima M
J Pharmacol Sci; 2005 Feb; 97(2):177-83. PubMed ID: 15725701
[TBL] [Abstract][Full Text] [Related]
79. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.
Beuers U; Trauner M; Jansen P; Poupon R
J Hepatol; 2015 Apr; 62(1 Suppl):S25-37. PubMed ID: 25920087
[TBL] [Abstract][Full Text] [Related]
80. The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years.
Bergasa NV
Med Hypotheses; 2018 Jan; 110():86-89. PubMed ID: 29317077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
